EGFR and lung carcinoma: In the 141 lung cancer cases divided into pre- (n = 31) and post- (n = 110) EGFR-TKI therapy, we found that the VAF distributions at the hotspots were significantly different (P = 0.018), mostly due to EGFR T790M (Fig. 2f).